{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:05:15Z","timestamp":1774418715255,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Regarding concurrent chemoradiotherapy (CCRT), the combination of docetaxel and cisplatin (DP regimen) is a promising option for treating head and neck squamous cell carcinoma (HNSCC) with a relatively low dose of cisplatin; however, its non-inferiority to other chemotherapies in efficacy and tolerability remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective multi-institutional study, the efficacy and safety of the DP regimen were compared with those of other chemotherapy regimens in patients who underwent CCRT for HNSCC. Overall survival, progression-free survival, and adverse effects\u2014including estimated glomerular filtration rate (eGFR)\u2014were evaluated as outcome measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Study results showed that a total of 211 patients were included. The prevalence of oropharyngeal, hypopharyngeal, and laryngeal cancer was 44%, 33%, and 17%, respectively. Overall response and recurrence rates were comparable between the DP regimen and high-dose CDDP alone. Although overall and progression-free survival tended to be longer with the DP regimen than with high-dose CDDP, the differences were not statistically significant. Neutropenia was more frequently observed with the DP regimen, but the chemotherapy completion rate was comparable to that of high-dose CDDP alone. Regarding renal function, eGFR significantly decreased with high-dose CDDP but not with the DP regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A combination of docetaxel and cisplatin in concurrent chemoradiotherapy was a favorable option for treating HNSCC with acceptable efficacy and manageable toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-026-02988-2","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T17:45:29Z","timestamp":1771609529000},"page":"730-739","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy and safety of docetaxel with cisplatin compared with other chemotherapies in definitive chemoradiotherapy for head and neck squamous cell carcinoma: a real-world study"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-671X","authenticated-orcid":false,"given":"Takumi","family":"Kumai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuto","family":"Izumiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misaki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Miyakoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisataka","family":"Ominato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motozumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Wakisaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihisa","family":"Kono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekiyo","family":"Yamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzo","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiya","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Yoshizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuji","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Bandoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"2988_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1102236","volume":"13","author":"G Gatta","year":"2023","unstructured":"Gatta G, Capocaccia R, Botta L (2023) Descriptive epidemiology of the head and neck cancers in old patients. Front Oncol 13:1102236","journal-title":"Front Oncol"},{"issue":"5","key":"2988_CR2","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/cncr.32583","volume":"126","author":"A Thompson-Harvey","year":"2020","unstructured":"Thompson-Harvey A, Yetukuri M, Hansen AR et al (2020) Rising incidence of late-stage head and neck cancer in the United States. Cancer 126(5):1090\u20131101","journal-title":"Cancer"},{"issue":"1","key":"2988_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01846-3","volume":"22","author":"N Khera","year":"2023","unstructured":"Khera N, Rajkumar AS, Abdulkader MAK et al (2023) Identification of multidrug chemoresistant genes in head and neck squamous cell carcinoma cells. Mol Cancer 22(1):146","journal-title":"Mol Cancer"},{"issue":"9","key":"2988_CR4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/jnci\/88.9.583","volume":"88","author":"M Merlano","year":"1996","unstructured":"Merlano M, Benasso M, Corvo R et al (1996) Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 88(9):583\u2013589","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2988_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","volume":"21","author":"DJ Adelstein","year":"2003","unstructured":"Adelstein DJ, Li Y, Adams GL et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21(1):92\u201398","journal-title":"J Clin Oncol"},{"issue":"11","key":"2988_CR6","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/hed.23794","volume":"37","author":"CP Rodriguez","year":"2015","unstructured":"Rodriguez CP, Adelstein DJ, Rybicki LA et al (2015) Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design. Head Neck 37(11):1583\u20131589","journal-title":"Head Neck"},{"issue":"10","key":"2988_CR7","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/jjco\/hyw100","volume":"46","author":"S Nakahara","year":"2016","unstructured":"Nakahara S, Hanamoto A, Seo Y et al (2016) Chemoradiotherapy with weekly low-dose docetaxel and cisplatin concurrent with radiation for patients with locally advanced nasopharyngeal carcinoma, followed by adjuvant chemotherapy for selected patients. Jpn J Clin Oncol 46(10):903\u2013910","journal-title":"Jpn J Clin Oncol"},{"issue":"11","key":"2988_CR8","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1200\/JCO.2017.74.9457","volume":"36","author":"V Noronha","year":"2018","unstructured":"Noronha V, Joshi A, Patil VM et al (2018) Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial. J Clin Oncol 36(11):1064\u20131072","journal-title":"J Clin Oncol"},{"issue":"9","key":"2988_CR9","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/1097-0142(19901101)66:9<1861::AID-CNCR2820660902>3.0.CO;2-I","volume":"66","author":"VA Marcial","year":"1990","unstructured":"Marcial VA, Pajak TF, Mohiuddin M et al (1990) Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the radiation therapy oncology group study 81-17. Cancer 66(9):1861\u20131868","journal-title":"Cancer"},{"issue":"10212","key":"2988_CR10","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212):1915\u20131928","journal-title":"Lancet"},{"issue":"12","key":"2988_CR11","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1200\/JCO.22.00332","volume":"41","author":"RI Haddad","year":"2023","unstructured":"Haddad RI, Harrington K, Tahara M et al (2023) Nivolumab plus Ipilimumab versus EXTREME regimen as first-line treatment for recurrent\/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651. J Clin Oncol 41(12):2166\u20132180","journal-title":"J Clin Oncol"},{"issue":"9","key":"2988_CR12","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1634\/theoncologist.2017-0015","volume":"22","author":"P Szturz","year":"2017","unstructured":"Szturz P, Wouters K, Kiyota N et al (2017) Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data. Oncologist 22(9):1056\u20131066","journal-title":"Oncologist"},{"issue":"1","key":"2988_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/coa.13876","volume":"47","author":"T Kumai","year":"2022","unstructured":"Kumai T, Komatsuda H, Wakisaka R et al (2022) Concurrent chemoradiotherapy with cisplatin and docetaxel for head and neck squamous cell carcinoma. Clin Otolaryngol 47(1):228\u2013233","journal-title":"Clin Otolaryngol"},{"issue":"10","key":"2988_CR14","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1002\/lary.26554","volume":"127","author":"M Nagasaka","year":"2017","unstructured":"Nagasaka M, Zaki M, Issa M et al (2017) Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck. Laryngoscope 127(10):2260\u20132264","journal-title":"Laryngoscope"},{"issue":"5","key":"2988_CR15","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/jjco\/hyu026","volume":"44","author":"M Komatsu","year":"2014","unstructured":"Komatsu M, Shiono O, Taguchi T et al (2014) Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck. Jpn J Clin Oncol 44(5):416\u2013421","journal-title":"Jpn J Clin Oncol"},{"key":"2988_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-102","volume":"13","author":"WK Bae","year":"2013","unstructured":"Bae WK, Hwang JE, Shim HJ et al (2013) Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck. BMC Cancer 13:102","journal-title":"BMC Cancer"},{"issue":"13","key":"2988_CR17","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1200\/JCO.22.00980","volume":"41","author":"VM Patil","year":"2023","unstructured":"Patil VM, Noronha V, Menon N et al (2023) Results of phase III randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based chemoradiation. J Clin Oncol 41(13):2350\u20132361","journal-title":"J Clin Oncol"},{"issue":"6","key":"2988_CR18","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M et al (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53(6):982\u2013992","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"2988_CR19","first-page":"E2151","volume":"38","author":"P Strojan","year":"2016","unstructured":"Strojan P, Vermorken JB, Beitler JJ et al (2016) Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: a systematic review. Head Neck 38(Suppl 1):E2151-2158","journal-title":"Head Neck"},{"key":"2988_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ctrv.2017.07.004","volume":"59","author":"A Al-Mamgani","year":"2017","unstructured":"Al-Mamgani A, van Werkhoven E, Navran A et al (2017) Contralateral regional recurrence after elective unilateral neck irradiation in oropharyngeal carcinoma: a literature-based critical review. Cancer Treat Rev 59:102\u2013108","journal-title":"Cancer Treat Rev"},{"key":"2988_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers8020021","author":"J Hoek","year":"2016","unstructured":"Hoek J, Bloemendal KM, van der Velden LA et al (2016) Nephrotoxicity as a dose-limiting factor in a high-dose cisplatin-based chemoradiotherapy regimen for head and neck carcinomas. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers8020021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2988_CR22","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1002\/cncr.24916","volume":"116","author":"CR Rasch","year":"2010","unstructured":"Rasch CR, Hauptmann M, Schornagel J et al (2010) Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: results of a randomized phase 3 trial. Cancer 116(9):2159\u20132165","journal-title":"Cancer"},{"issue":"1","key":"2988_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41581-022-00631-7","volume":"19","author":"C Tang","year":"2023","unstructured":"Tang C, Livingston MJ, Safirstein R et al (2023) Cisplatin nephrotoxicity: new insights and therapeutic implications. Nat Rev Nephrol 19(1):53\u201372","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"2988_CR24","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.ijrobp.2012.05.008","volume":"84","author":"JS Cooper","year":"2012","unstructured":"Cooper JS, Zhang Q, Pajak TF et al (2012) Long-term follow-up of the RTOG 9501\/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 84(5):1198\u20131205","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"2988_CR25","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2215\/CJN.08070715","volume":"11","author":"S Latcha","year":"2016","unstructured":"Latcha S, Jaimes EA, Patil S et al (2016) Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol 11(7):1173\u20131179","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2988_CR26","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.oraloncology.2011.10.005","volume":"48","author":"V Espeli","year":"2012","unstructured":"Espeli V, Zucca E, Ghielmini M et al (2012) Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer. Oral Oncol 48(3):266\u2013271","journal-title":"Oral Oncol"},{"issue":"18","key":"2988_CR27","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1016\/j.ejca.2009.06.032","volume":"45","author":"R Skinner","year":"2009","unstructured":"Skinner R, Parry A, Price L et al (2009) Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors. Eur J Cancer 45(18):3213\u20133219","journal-title":"Eur J Cancer"},{"key":"2988_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.oraloncology.2016.04.003","volume":"57","author":"D Rades","year":"2016","unstructured":"Rades D, Seidl D, Janssen S et al (2016) Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer? Oral Oncol 57:40\u201345","journal-title":"Oral Oncol"},{"issue":"17","key":"2988_CR29","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa070956","volume":"357","author":"MR Posner","year":"2007","unstructured":"Posner MR, Hershock DM, Blajman CR et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357(17):1705\u20131715","journal-title":"N Engl J Med"},{"issue":"2","key":"2988_CR30","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3892\/ijo.2015.3291","volume":"48","author":"S Miyanaga","year":"2016","unstructured":"Miyanaga S, Ninomiya I, Tsukada T et al (2016) Concentration-dependent radiosensitizing effect of docetaxel in esophageal squamous cell carcinoma cells. Int J Oncol 48(2):517\u2013524","journal-title":"Int J Oncol"},{"issue":"5","key":"2988_CR31","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.ijrobp.2014.12.032","volume":"91","author":"H Inohara","year":"2015","unstructured":"Inohara H, Takenaka Y, Yoshii T et al (2015) Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 91(5):934\u2013941","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2988_CR32","first-page":"4135","volume":"24","author":"H Inohara","year":"2004","unstructured":"Inohara H, Inoue T, Akahani S et al (2004) Concurrent chemoradiotherapy with cisplatin and docetaxel for advanced head and neck cancer: a phase I study. Anticancer Res 24(6):4135\u20134140","journal-title":"Anticancer Res"},{"issue":"20","key":"2988_CR33","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1200\/JCO.2009.24.7577","volume":"28","author":"Y Segawa","year":"2010","unstructured":"Segawa Y, Kiura K, Takigawa N et al (2010) Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 28(20):3299\u20133306","journal-title":"J Clin Oncol"},{"issue":"4","key":"2988_CR34","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00432-013-1373-9","volume":"139","author":"J Pu","year":"2013","unstructured":"Pu J, Qin SS, Ding JX et al (2013) A randomized controlled study of single-agent cisplatin and radiotherapy versus docetaxel\/cisplatin and radiotherapy in high-risk early-stage cervical cancer after radical surgery. J Cancer Res Clin Oncol 139(4):703\u2013708","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2988_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13014-020-01518-2","volume":"15","author":"Q Liu","year":"2020","unstructured":"Liu Q, Xia Y, Chen Y et al (2020) A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and\/or M1 lymph node metastasis or locoregional recurrence. Radiat Oncol 15(1):75","journal-title":"Radiat Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-02988-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-02988-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-02988-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:13:39Z","timestamp":1774415619000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-02988-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2988"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-02988-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"6 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study adhered to the principles of the Declaration of Helsinki. The study design was approved by the Institutional Review Board of Asahikawa Medical University, Asahikawa, Japan (approval number: 20054 and 25111).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained using the opt-out method.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}}]}}